PT - JOURNAL ARTICLE AU - Gokhan Tut AU - Tara Lancaster AU - Megan S. Butler AU - Panagiota Sylla AU - Eliska Spalkova AU - David Bone AU - Nayandeep Kaur AU - Christopher Bentley AU - Umayr Amin AU - Azar T. Jadir AU - Samuel Hulme AU - Morenike Ayodel AU - Alexander C. Dowell AU - Hayden Pearce AU - Sandra Margielewska-Davies AU - Kriti Verma AU - Samantha Nicol AU - Jusnara Begum AU - D. Blakeway AU - Elizabeth Jinks AU - Elif Tut AU - Rachel Bruton AU - Maria Krutikov AU - Madhumita Shrotri AU - Rebecca Giddings AU - Borscha Azmi AU - Chris Fuller AU - Aidan Irwin-Singer AU - Andrew Hayward AU - Andrew Copas AU - Laura Shallcross AU - Paul Moss TI - Robust SARS-CoV-2-specific and heterologous immune responses after natural infection in elderly residents of Long-Term Care Facilities AID - 10.1101/2021.08.13.21261889 DP - 2021 Jan 01 TA - medRxiv PG - 2021.08.13.21261889 4099 - http://medrxiv.org/content/early/2021/08/18/2021.08.13.21261889.short 4100 - http://medrxiv.org/content/early/2021/08/18/2021.08.13.21261889.full AB - Long term care facilities (LTCF) provide residential and/or nursing care support for frail and elderly people and many have suffered from a high prevalence of SARS-CoV-2 infection. Although mortality rates have been high in LTCF residents there is little information regarding the features of SARS-CoV-2-specific immunity after infection in this setting or how this may influence immunity to other infections. We studied humoral and cellular immunity against SARS-CoV-2 in 152 LTCF staff and 124 residents over a prospective 4-month period shortly after the first wave of infection and related viral serostatus to heterologous immunity to other respiratory viruses and systemic inflammatory markers. LTCF residents developed high levels of antibodies against spike protein and RBD domain which were stable over 4 months of follow up. Nucleocapsid-specific responses were also elevated in elderly donors but showed waning across all populations. Antibodies showed stable and equivalent levels of functional inhibition against spike-ACE2 binding in all age groups with comparable activity against viral variants of concern. SARS-CoV-2 seropositive donors showed high levels of antibodies to other beta-coronaviruses but serostatus did not impact humoral immunity to influenza or RSV. SARS-CoV-2-specific cellular responses were equivalent across the life course but virus-specific populations showed elevated levels of activation in older donors. LTCF residents who are survivors of SARS-CoV-2 infection thus show robust and stable immunity which does not impact responses to other seasonal viruses. These findings augur well for relative protection of LTCF residents to re-infection. Furthermore, they underlie the potent influence of previous infection on the immune response to Covid-19 vaccine which may prove to be an important determinant of future vaccine strategy.One sentence summery Care home residents show waning of nucleocapsid specific antibodies and enhanced expression of activation markers on SARS-CoV-2 specific cellsCompeting Interest StatementThe authors have declared no competing interest.Funding StatementUK Government Department of Health and Social Care. The funder had no role in the study design, data collection, data analysis, data interpretation or writing of the report. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval for this study was obtained from the South Central - Hampshire B Research Ethics Committee, REC Ref: 20/SC/0238All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDe-identified test results and limited meta-data will be made available for use by researchers in future studies, subject to appropriate research ethical approvals, once the VIVALDI study cohort has been finalised. These datasets will be accessible via the Health Data Research UK Gateway https://www.healthdatagateway.org/.